Place of meta-[131I]iodobenzylguanidine in the treatment of neuroblastoma: the Genoa experience.

A. Garaventa, C. Pianca, M. Conte, M. Nigro, B. De Bernardi, F. Claudiani, P. Stimamiglio, L. Bertolazzi, M. Cabria, G. P. Villavecchia

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The aim of this paper is to focus on our previous experience with the treatment of Group 3 and 4 neuroblastoma patients and on the therapeutic use of [131I]MIBG, to better define the role of this radioactive drug in the treatment of neuroblastoma (NB). Analysis of the studies on Group 3 patients treated with chemotherapy and surgery showed that the progression-free survival (PFS) increased from 45% for patients treated before 1985 to 63% for patients treated in the period of 1985-1989 and to 78% for patients treated after 1989. [131I]MIBG administered in 17 Group 3 patients who did not achieve a radical excision of the primary resulted in 7 partial response (PR) and 5 minor response (MR), with 10 cases of long term survival. Results in Group 4 patients confirmed the good prognosis in the subset of children aged 6-12 months at diagnosis (PFS 86% at 5 years). In patients aged > 12 months at diagnosis intensive induction chemotherapy induced a higher response rate of 69% and PFS was 26% at 5 years. [131I]MIBG administered in advanced stage 4 patients induced a response in 50% of the cases (2 complete response [CR], 13 PR and 2 MR out of 34 children) and 8 children treated for residual primary (4 cases) or residual bone metastases (4 cases) are long term survivors. We conclude that [131I]MIBG is the treatment of choice in Group 3 patient with a residual primary tumor and could contribute to consolidate the response obtained in Group 4 patients.

Original languageEnglish
Pages (from-to)58-60
Number of pages3
JournalQuarterly Journal of Nuclear Medicine
Volume39
Issue number4 Suppl 1
Publication statusPublished - Dec 1995

Fingerprint

3-Iodobenzylguanidine
Neuroblastoma
Therapeutics
Disease-Free Survival
Induction Chemotherapy
Residual Neoplasm
Therapeutic Uses
Survivors

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Garaventa, A., Pianca, C., Conte, M., Nigro, M., De Bernardi, B., Claudiani, F., ... Villavecchia, G. P. (1995). Place of meta-[131I]iodobenzylguanidine in the treatment of neuroblastoma: the Genoa experience. Quarterly Journal of Nuclear Medicine, 39(4 Suppl 1), 58-60.

Place of meta-[131I]iodobenzylguanidine in the treatment of neuroblastoma : the Genoa experience. / Garaventa, A.; Pianca, C.; Conte, M.; Nigro, M.; De Bernardi, B.; Claudiani, F.; Stimamiglio, P.; Bertolazzi, L.; Cabria, M.; Villavecchia, G. P.

In: Quarterly Journal of Nuclear Medicine, Vol. 39, No. 4 Suppl 1, 12.1995, p. 58-60.

Research output: Contribution to journalArticle

Garaventa, A, Pianca, C, Conte, M, Nigro, M, De Bernardi, B, Claudiani, F, Stimamiglio, P, Bertolazzi, L, Cabria, M & Villavecchia, GP 1995, 'Place of meta-[131I]iodobenzylguanidine in the treatment of neuroblastoma: the Genoa experience.', Quarterly Journal of Nuclear Medicine, vol. 39, no. 4 Suppl 1, pp. 58-60.
Garaventa, A. ; Pianca, C. ; Conte, M. ; Nigro, M. ; De Bernardi, B. ; Claudiani, F. ; Stimamiglio, P. ; Bertolazzi, L. ; Cabria, M. ; Villavecchia, G. P. / Place of meta-[131I]iodobenzylguanidine in the treatment of neuroblastoma : the Genoa experience. In: Quarterly Journal of Nuclear Medicine. 1995 ; Vol. 39, No. 4 Suppl 1. pp. 58-60.
@article{b71f633ca07945ebbc0f13e5811ee9c1,
title = "Place of meta-[131I]iodobenzylguanidine in the treatment of neuroblastoma: the Genoa experience.",
abstract = "The aim of this paper is to focus on our previous experience with the treatment of Group 3 and 4 neuroblastoma patients and on the therapeutic use of [131I]MIBG, to better define the role of this radioactive drug in the treatment of neuroblastoma (NB). Analysis of the studies on Group 3 patients treated with chemotherapy and surgery showed that the progression-free survival (PFS) increased from 45{\%} for patients treated before 1985 to 63{\%} for patients treated in the period of 1985-1989 and to 78{\%} for patients treated after 1989. [131I]MIBG administered in 17 Group 3 patients who did not achieve a radical excision of the primary resulted in 7 partial response (PR) and 5 minor response (MR), with 10 cases of long term survival. Results in Group 4 patients confirmed the good prognosis in the subset of children aged 6-12 months at diagnosis (PFS 86{\%} at 5 years). In patients aged > 12 months at diagnosis intensive induction chemotherapy induced a higher response rate of 69{\%} and PFS was 26{\%} at 5 years. [131I]MIBG administered in advanced stage 4 patients induced a response in 50{\%} of the cases (2 complete response [CR], 13 PR and 2 MR out of 34 children) and 8 children treated for residual primary (4 cases) or residual bone metastases (4 cases) are long term survivors. We conclude that [131I]MIBG is the treatment of choice in Group 3 patient with a residual primary tumor and could contribute to consolidate the response obtained in Group 4 patients.",
author = "A. Garaventa and C. Pianca and M. Conte and M. Nigro and {De Bernardi}, B. and F. Claudiani and P. Stimamiglio and L. Bertolazzi and M. Cabria and Villavecchia, {G. P.}",
year = "1995",
month = "12",
language = "English",
volume = "39",
pages = "58--60",
journal = "Journal of Nuclear Medicine and Allied Sciences",
issn = "1124-3937",
publisher = "Minerva Medica",
number = "4 Suppl 1",

}

TY - JOUR

T1 - Place of meta-[131I]iodobenzylguanidine in the treatment of neuroblastoma

T2 - the Genoa experience.

AU - Garaventa, A.

AU - Pianca, C.

AU - Conte, M.

AU - Nigro, M.

AU - De Bernardi, B.

AU - Claudiani, F.

AU - Stimamiglio, P.

AU - Bertolazzi, L.

AU - Cabria, M.

AU - Villavecchia, G. P.

PY - 1995/12

Y1 - 1995/12

N2 - The aim of this paper is to focus on our previous experience with the treatment of Group 3 and 4 neuroblastoma patients and on the therapeutic use of [131I]MIBG, to better define the role of this radioactive drug in the treatment of neuroblastoma (NB). Analysis of the studies on Group 3 patients treated with chemotherapy and surgery showed that the progression-free survival (PFS) increased from 45% for patients treated before 1985 to 63% for patients treated in the period of 1985-1989 and to 78% for patients treated after 1989. [131I]MIBG administered in 17 Group 3 patients who did not achieve a radical excision of the primary resulted in 7 partial response (PR) and 5 minor response (MR), with 10 cases of long term survival. Results in Group 4 patients confirmed the good prognosis in the subset of children aged 6-12 months at diagnosis (PFS 86% at 5 years). In patients aged > 12 months at diagnosis intensive induction chemotherapy induced a higher response rate of 69% and PFS was 26% at 5 years. [131I]MIBG administered in advanced stage 4 patients induced a response in 50% of the cases (2 complete response [CR], 13 PR and 2 MR out of 34 children) and 8 children treated for residual primary (4 cases) or residual bone metastases (4 cases) are long term survivors. We conclude that [131I]MIBG is the treatment of choice in Group 3 patient with a residual primary tumor and could contribute to consolidate the response obtained in Group 4 patients.

AB - The aim of this paper is to focus on our previous experience with the treatment of Group 3 and 4 neuroblastoma patients and on the therapeutic use of [131I]MIBG, to better define the role of this radioactive drug in the treatment of neuroblastoma (NB). Analysis of the studies on Group 3 patients treated with chemotherapy and surgery showed that the progression-free survival (PFS) increased from 45% for patients treated before 1985 to 63% for patients treated in the period of 1985-1989 and to 78% for patients treated after 1989. [131I]MIBG administered in 17 Group 3 patients who did not achieve a radical excision of the primary resulted in 7 partial response (PR) and 5 minor response (MR), with 10 cases of long term survival. Results in Group 4 patients confirmed the good prognosis in the subset of children aged 6-12 months at diagnosis (PFS 86% at 5 years). In patients aged > 12 months at diagnosis intensive induction chemotherapy induced a higher response rate of 69% and PFS was 26% at 5 years. [131I]MIBG administered in advanced stage 4 patients induced a response in 50% of the cases (2 complete response [CR], 13 PR and 2 MR out of 34 children) and 8 children treated for residual primary (4 cases) or residual bone metastases (4 cases) are long term survivors. We conclude that [131I]MIBG is the treatment of choice in Group 3 patient with a residual primary tumor and could contribute to consolidate the response obtained in Group 4 patients.

UR - http://www.scopus.com/inward/record.url?scp=0029421731&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029421731&partnerID=8YFLogxK

M3 - Article

C2 - 9002751

AN - SCOPUS:0029421731

VL - 39

SP - 58

EP - 60

JO - Journal of Nuclear Medicine and Allied Sciences

JF - Journal of Nuclear Medicine and Allied Sciences

SN - 1124-3937

IS - 4 Suppl 1

ER -